SNOA News and Press, Sonoma Pharmaceuticals Inc. From 01/25/23

Sonoma Pharmaceuticals ( NASDAQ: SNOA ) said its Microcyn Rx products have received a Distribution and Pricing Agreement (DAPA) for distribution by the Defense Logistics Agency (DLA). The DAPA enables Sonoma's partner EMC Pharma to enter into distribution agreements for Micr...

BOULDER, CO / ACCESSWIRE / January 25, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral a...

BOULDER, CO / ACCESSWIRE / January 4, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral ...

Sonoma Pharmaceuticals press release ( NASDAQ: SNOA ): Q2 GAAP EPS of -$0.33. Revenue of $3.3M (-11.8% Y/Y). EBITDAS loss for the quarter ended September 30, 2022 of $0.6M decreased $0.3M, compared to an EBITDAS loss of $0.9M for the same period last year. For fu...

International sales increased by 18% in the six months ended September 30, 2022 compared to the same period prior year Gross profit percentage continues to trend upwards with the quarter ended September 30, 2022, coming in at 40% compared to 33% same period prior year Operating lo...

3 Reasons Why Penny Stocks Could Be Worth Buying Penny stocks are an attractive investment choice for many investors due to their low cost and high potential for return. These stocks typically trade on the same exchanges that investors are used to but sometimes they can have less visibi...

Benefitfocus BNFT +48% after hours on $570M merger with Voya Financial. Sonoma Pharmaceuticals ( NASDAQ: SNOA ) +31% . Arcturus Therapeutics Holdings ( NASDAQ: ARCT ) +30% Collaboration with CSL to Develop and Commercialize Self-amplifying mRN...

BOULDER, CO / ACCESSWIRE / October 27, 2022 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and...

BOULDER, CO / ACCESSWIRE / October 6, 2022 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, and dermatological condi...

Sonoma Pharmaceuticals press release ( NASDAQ: SNOA ): Q1 GAAP EPS of -$0.29. Revenue of $3.99M (+8.4% Y/Y). For further details see: Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99M